ARGX-117

ARGX-117 is designed to be a humanized sweeping antibody that binds specifically to C2 in a pH- and Ca2+- dependent manner. C2 is a protein in the complement cascade which, when activated, leads to cell destruction. Binding of ARGX-117 is intended to inhibit the function of C2 and downstream complement activation.

By blocking complement activity, ARGX-117 has the potential to reduce tissue inflammation and the adaptive immune response. Through this proposed mechanism, ARGX-117 could represent a broad pipeline opportunity across severe autoimmune indications.

Pipeline

ARGX-117

Target
C2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
  • ARGX-117 is designed to block complement activity with potential to reduce tissue inflammation and the adaptive immune response
  • IV ARGX-117 and SC ARGX-117 (enabled with Halozyme's ENHANZE® drug delivery technology)